Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytop
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
The U.S. Food and Drug Administration approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that
read more » Discuss Add this link to...Bury Add to:
| Bookmarks